J&J buys into spine test firm
This article was originally published in The Gray Sheet
Executive SummaryJohnson & Johnson leads a $15.3 million financing round and enters a strategic collaboration with Axial Biotech to accelerate the start-up's development of a genetic test to pre-symptomatically predict which cases of scoliosis, or abnormal curvature of the spine, are likely to progress and require intervention, firms announce March 27. Axial hopes to launch the first-of-its-kind test in late 2008, and estimates a U.S. market size of $180 million. The Raynham, Mass. firm also is developing minimally invasive devices for spine surgery...
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.